Literature DB >> 29259045

Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden.

Karin Bengtsson1, Helena Forsblad-d'Elia1,2, Elisabeth Lie1,3, Eva Klingberg1, Mats Dehlin1, Sofia Exarchou4, Ulf Lindström1, Johan Askling5, Lennart T H Jacobsson1.   

Abstract

OBJECTIVES: To describe the incidence of atrioventricular (AV) block II-III, atrial fibrillation (AF), pacemaker implantation (PM) and aortic regurgitation in patients with ankylosing spondylitis (AS), undifferentiated spondyloarthritis (uSpA) and psoriatic arthritis (PsA) compared with the general population (GP) and with each other.
METHODS: A prospective nationwide study with cohorts of patients with AS (n=6448), PsA (n=16 063) and uSpA (n=5190) and a GP (n=2 66 435) cohort, identified in 2001-2009 in the Swedish National Patient and Population registers. Follow-up began on 1 January 2006 and ended at event, death, emigration or 31 December 2012. Age-standardised and sex-standardised incidence rates and hazard ratios (HRs) were calculated.
RESULTS: The highest incidence rates were noted for AF (5.5-7.4 events per 1000 person-years), followed by PM (1.0-2.0 events per 1000 person-years). HRs for AV block, AF, PM and aortic regurgitation were significantly increased in AS (HRs 2.3, 1.3, 2.1 and 1.9), uSpA (HRs 2.9, 1.3, 1.9 and 2.0) and PsA (HRs 1.5, 1.5, 1.6 and 1.8) compared with the GP cohort. The highest HRs were seen for AV block in male uSpA (HR 4.2) and AS (HR 2.5) compared with GP. Compared with PsA, significantly increased HRs were noted for PM (HR 1.5) in AS and for AV block (HR 1.8) in uSpA.
CONCLUSIONS: Patients with SpA are at increased risk of aortic regurgitation, cardiac rhythm disturbances and, as a probable consequence, also PM. Particularly for AF, the most common arrhythmia, increased caution is warranted, whereas AV block should be looked for especially in men with AS or uSpA. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  ankylosing spondylitis; cardiovascular disease; psoriatic arthritis; spondyloarthritis

Mesh:

Year:  2017        PMID: 29259045     DOI: 10.1136/annrheumdis-2017-212189

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

2.  Ankylosing Spondylitis and Risk of Cardiac Arrhythmia and Conduction Disorders: A Systematic Review and Meta-analysis.

Authors:  Negar Morovatdar; Gerald F Watts; Yones Bondarsahebi; Fatemeh Goldani; Elham Rahmanipour; Ramin Rezaee; Amirhossein Sahebkar
Journal:  Curr Cardiol Rev       Date:  2021

3.  Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study.

Authors:  Eva Klingberg; Annelie Bilberg; Sofia Björkman; Martin Hedberg; Lennart Jacobsson; Helena Forsblad-d'Elia; Hans Carlsten; Björn Eliasson; Ingrid Larsson
Journal:  Arthritis Res Ther       Date:  2019-01-11       Impact factor: 5.156

4.  Transient severe conduction disturbances associated with ankylosing spondylitis.

Authors:  Kuniyasu Ikeoka; Nagahiro Nishikawa; Masayuki Sakakibara; Keisuke Kawamoto; Shiro Hoshida
Journal:  J Arrhythm       Date:  2019-07-04

5.  Commentary: Systemic effects of IL-17 in inflammatory arthritis.

Authors:  Pietro Enea Lazzerini; Franco Laghi-Pasini; Mohamed Boutjdir; Pier Leopoldo Capecchi
Journal:  Front Cardiovasc Med       Date:  2019-12-10

6.  Echocardiographic and Electrocardiographic Findings in Patients with Ankylosing Spondylitis without Cardiovascular Risk Factors.

Authors:  Simin Almasi; Behzad Farahani; Niloufar Samiei; Yousef Rezaei; Habib Mahmoodi; Mostafa Qorbani
Journal:  J Tehran Heart Cent       Date:  2020-04

7.  Lifetime Risks of Valvular Heart Disease and Pacemaker Use in Patients With Ankylosing Spondylitis.

Authors:  Michael M Ward
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

8.  Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study.

Authors:  Karin Bengtsson; Eva Klingberg; Anna Deminger; Hanna Wallberg; Lennart T H Jacobsson; Lennart Bergfeldt; Helena Forsblad-d'Elia
Journal:  RMD Open       Date:  2019-11-13

9.  Heart Involvement in a Moroccan Population with Spondyloarthritis: A Cross-sectional Study.

Authors:  Jalila Eddarami; Hamida Azzouzi; Linda Ichchou
Journal:  J Saudi Heart Assoc       Date:  2021-07-08

10.  Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study.

Authors:  Wun-Zhih Siao; Chin-Hsiu Liu; Yu-Hsun Wang; James Cheng-Chung Wei; Gwo-Ping Jong
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-18       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.